Tag
A 12-week prospective study demonstrates tirzepatide significantly improves insulin sensitivity in obese Japanese patients with type 2 diabetes, independent of weight loss, as assessed by hyperinsulinaemic-euglycaemic clamp.
Real-world analysis shows semaglutide and tirzepatide reduce hospitalization for heart failure or all-cause mortality by over 40% in patients with cardiometabolic HFpEF, with no significant difference between the two drug options.
Tirzepatide significantly improves health-related quality of life alongside weight reduction in adults with obesity or overweight, especially those experiencing physical function limitations, according to SURMOUNT-3 trial results.
Post hoc analysis of the SURMOUNT-CN trial shows tirzepatide markedly reduces the 10-year predicted risk of type 2 diabetes in Chinese individuals with overweight or obesity, regardless of baseline BMI or prediabetes status.
Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.
A new study reveals combining tirzepatide and hormone therapy significantly boosts weight loss in postmenopausal women, offering a promising approach to managing obesity-related health risks.
New anti-obesity medications are transforming weight management, challenging old paradigms, and raising new questions about the future of dieting and health.